Small trial suggests Eli Lilly's coronavirus antibody drug could reduce patients' hospitalization odds


Eli Lilly's monoclonal coronavirus antibody drug is off to a "good start" after the pharmaceutical giant completed a small clinical trial, Stat News reports.
Only about 450 patients were enrolled in the trial, so there's a long way to go before Lilly finds anything definitive, but Stat reports the medicine — a manufactured version of the naturally-occurring antibodies the body produces to fend off the virus — appeared to reduce patients' hospitalization odds. Only 1.7 percent of the patients who received the drug went to the emergency room or were hospitalized, compared to 6 percent who took a placebo.
Again, it's unclear if that will hold up with further study, but Daniel Skovronsky, Lilly's chief scientific officer, said the early data are "extremely exciting" and "should give us confidence that neutralizing antibodies are going to be an important part of the solution" to the pandemic. Skovonrsky said the company will discuss additional clinical trials with regulators, as well as options like an emergency use authorization.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
On the latter point, Eric Topol, the director and founder of the Scripps Research Translational Institute, suggested pumping the brakes. Topol is encouraged by the initial results, but doesn't think the drug currently "would qualify to even consider" an EUA. Read more findings from the trial at Stat News.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Tim is a staff writer at The Week and has contributed to Bedford and Bowery and The New York Transatlantic. He is a graduate of Occidental College and NYU's journalism school. Tim enjoys writing about baseball, Europe, and extinct megafauna. He lives in New York City.
-
Having a mayor: Starmer's struggles with devolved leaders
Talking Point Andy Burnham made public criticisms of the Labour government policies without specifically naming Keir Starmer or Rachel Reeves
-
Why is Nasa facing a crisis?
Today's Big Question Trump administration proposes 25% cut to national space agency's budget in 'extinction-level event'
-
The 50-year battle for Western Sahara
The Explainer UK is latest country to back Moroccan plan to end decades-long dispute with Algerian-backed Polisario Front
-
RFK Jr. scraps Covid shots for pregnant women, kids
Speed Read The Health Secretary announced a policy change without informing CDC officials
-
New FDA chiefs limit Covid-19 shots to elderly, sick
speed read The FDA set stricter approval standards for booster shots
-
US overdose deaths plunged 27% last year
speed read Drug overdose still 'remains the leading cause of death for Americans aged 18-44,' said the CDC
-
Trump seeks to cut drug prices via executive order
speed read The president's order tells pharmaceutical companies to lower prescription drug prices, but it will likely be thrown out by the courts
-
RFK Jr. visits Texas as 2nd child dies from measles
Speed Read An outbreak of the vaccine-preventable disease continues to grow following a decade of no recorded US measles deaths
-
Shingles vaccine cuts dementia risk, study finds
Speed Read Getting vaccinated appears to significantly reduce the chances of developing Alzheimer's and other forms of dementia
-
Measles outbreak spreads, as does RFK Jr.'s influence
Speed Read The outbreak centered in Texas has grown to at least three states and Health Secretary Robert F. Kennedy Jr. is promoting unproven treatments
-
RFK Jr. offers alternative remedies as measles spreads
Speed Read Health secretary Robert F. Kennedy Jr. makes unsupported claims about containing the spread as vaccine skepticism grows